Cellebrite DI (NASDAQ:CLBT) Price Target Cut to $18.00 by Analysts at Needham & Company LLC

Cellebrite DI (NASDAQ:CLBT) had its target price trimmed by Needham & Company LLC from $24.00 to $18.00 in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Bank of America raised their target price on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. JPMorgan Chase & Co. upped their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Wall Street Zen downgraded Cellebrite DI from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Lake Street Capital lifted their price target on Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $13.70 on Thursday. Cellebrite DI has a 52-week low of $13.10 and a 52-week high of $25.03. The stock has a fifty day moving average of $17.12 and a 200 day moving average of $16.98. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of 44.19, a P/E/G ratio of 1.99 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.14. The business had revenue of $128.82 million for the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 21.41% and a net margin of 16.47%.The company’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.10 EPS. Equities analysts forecast that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Advisors Asset Management Inc. increased its holdings in shares of Cellebrite DI by 79.0% in the fourth quarter. Advisors Asset Management Inc. now owns 9,945 shares of the company’s stock worth $179,000 after buying an additional 4,388 shares during the period. HRT Financial LP increased its stake in Cellebrite DI by 51.2% in the 4th quarter. HRT Financial LP now owns 339,909 shares of the company’s stock worth $6,128,000 after purchasing an additional 115,045 shares during the period. Marex Group plc bought a new stake in Cellebrite DI in the fourth quarter valued at approximately $602,000. New York State Common Retirement Fund boosted its stake in shares of Cellebrite DI by 221.7% during the fourth quarter. New York State Common Retirement Fund now owns 467,842 shares of the company’s stock valued at $8,435,000 after purchasing an additional 322,409 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Cellebrite DI by 3.7% during the fourth quarter. Swiss National Bank now owns 217,800 shares of the company’s stock valued at $3,927,000 after purchasing an additional 7,700 shares during the period. 45.88% of the stock is owned by institutional investors.

Key Cellebrite DI News

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Q4 2025 results: Revenue of $128.8M (up 18% YoY) and ARR +21% to $480.8M; net income and adjusted EBITDA margins expanded, and management issued FY 2026 revenue guidance above consensus — a fundamental beat and constructive outlook. Read More.
• Positive Sentiment: Q4 EPS matched consensus ($0.14) and revenue beat estimates, supporting the company’s growth narrative and margins improvement. Read More.
• Neutral Sentiment: Earnings materials and call transcripts are available for deeper diligence (slides and call transcripts reiterate strategy and bookings detail). Read More. Read More.
• Neutral Sentiment: Coverage pieces assessing valuation and longer-term outlook published — useful for modeling but not immediate catalysts. Read More.
• Neutral Sentiment: Reported short‑interest entries show zeros/NaN across recent filings — appears to be a data anomaly rather than a meaningful short‑squeeze signal. (No actionable short‑interest change is evident.)
• Negative Sentiment: Analyst update: Needham cut its price target from $24 to $18 (still a “buy”), reducing near-term upside expectations and likely contributing to selling pressure. Read More.
• Negative Sentiment: Technical / flow pressure: shares are trading below both the 50- and 200-day moving averages and volume is elevated versus average — conditions that can amplify downside after a mixed reaction to results.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.